Kodak Q3 2026: $276 Million in Revenue, Rochester Pharma Manufacturing as the Growth Engine
The Short Version
- Kodak Q3 2026 revenue hit $276 million, up 3%, with net income jumping from $13 million to $21 million — the bottom line improvement that most directly reflects the Rochester turnaround.
- Advanced Materials and Chemicals, anchored at Eastman Business Park, grew 21% year-over-year to $99 million, now making up 36% of total Kodak revenue.
- In early 2026, Kodak launched four regulated pharmaceutical products from its Rochester plant — two formulations of phosphate-buffered saline and two of water for injection.
- Print revenue, still Kodak's largest segment at $165 million, fell 7% year-over-year, confirming AM&C is the company's growth vector.
- Kodak employs roughly 1,300 Rochester-area workers and has reinvested hundreds of millions of dollars in Eastman Business Park's utilities, labs, and production capabilities.
Eastman Business Park has 88 reactors and a 117-megawatt power plant, built to produce film at a scale that once made it one of the largest integrated manufacturing complexes in the United States. That infrastructure is now making pharmaceutical products for healthcare markets — and showing up in Kodak's quarterly results.
Kodak reported Q3 2026 revenue of $276 million this week, up 3% from $269 million in the same period last year. Net income rose from $13 million to $21 million. The company generated $27 million in cash during the quarter. The segment driving those numbers is Advanced Materials and Chemicals, which operates primarily out of Rochester.
Kodak Q3 2026 by the Numbers
Kodak Q3 2026 by the Numbers
AM&C revenue came in at $99 million for the quarter, up 21% from $82 million in Q3 2025. CEO Jim Continenza, in Kodak's Q3 2026 earnings press release: "Our primary growth engine, AM&C, is now our fastest growing, most profitable unit."
Print revenue fell to $165 million from $177 million — a 7% decline from Q3 2025. Print still makes up the largest share of Kodak's total, but the direction is set. AM&C grew by $17 million year-over-year while print contracted by $12 million.
What Is Actually Being Made at Eastman Business Park
What Is Actually Being Made at Eastman Business Park
The park on Lake Avenue in northwest Rochester holds some 100 independent companies alongside Kodak's own operations. In early 2026, Kodak launched four regulated pharmaceutical products from its Good Manufacturing Practice-compliant facility at the park: two formulations of phosphate-buffered saline and two of water for injection. These are laboratory staples — solutions used in cell biology, diagnostic testing, and clinical workflows across healthcare systems.
Kodak has also made a multimillion-dollar investment in a new pharmaceutical manufacturing facility at the park to produce FDA-regulated diagnostic test reagents. The connection between Kodak's film chemistry history and its pharmaceutical manufacturing is deliberate. As Continenza told Outsourced Pharma in May 2026: "Film is essentially small-molecule chemistry. That's what we're phenomenal at."
What This Means for Rochester's 1,300 Kodak Workers
What This Means for Rochester's 1,300 Kodak Workers
Kodak employs roughly 1,300 Rochester-area workers. Eastman Business Park now holds the AM&C operations that generated those Q3 numbers. The company poured hundreds of millions of dollars into the park — upgraded utilities, labs, and production capabilities — after a period when the campus's future was uncertain.
Continenza has called the park "my jewel." The Q3 results give that description a revenue figure: $99 million in a single quarter, growing at 21% annually, out of a site on Lake Avenue that was built to make film and is now making drugs. Those 1,300 workers are what turned a reinvestment thesis into a quarterly result.
Content ID: ADBrNHo9XftqYn9ISZYbldIg
See an error? Tell us.
Comments
Share with the Community